Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Primarily hepatic via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Volume of distribution is 3-5 L/kg, indicating extensive tissue distribution beyond the vascular compartment.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral bioavailability is approximately 30-40% due to extensive first-pass metabolism by CYP3A4 in the liver and gut wall.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Cr Cl <30 m L/min: 2.5 mg once daily; increase cautiously. Cr Cl ≥30 m L/min: no adjustment needed.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh A: use with caution, start at 2.5 mg daily. Child-Pugh B or C: not recommended due to extensive hepatic metabolism.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Safety and efficacy not established; no standard pediatric dosing.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Initiate at 2.5 mg once daily; increase slowly due to increased systemic exposure and risk of hypotension.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None
Use with caution in patients with heart failure, aortic stenosis, or severe left ventricular dysfunction.,May cause hypotension, especially with concurrent beta-blocker use.,Avoid abrupt withdrawal; taper gradually.,Monitor for peripheral edema, particularly in the lower extremities.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to isradipine or any of its components.,Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contraindicated.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Grapefruit juice increases isradipine bioavailability; avoid concurrent use. No other significant food interactions. Maintain consistent salt intake to avoid blood pressure fluctuations.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
First trimester: No adequate studies; animal reproduction studies not available. Second trimester: Possible fetal bradycardia, hypotension, hypoxia if used after 20 weeks due to calcium channel blocker effects. Third trimester: Increased risk of fetal hypoxia, oligohydramnios, and neonatal complications. Avoid use in pregnancy unless benefit outweighs risk.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Excretion in human milk unknown; M/P ratio not determined. Risk of hypotension in neonate. Use with caution, monitor infant for signs of hypotension.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume, but no studies. Use lowest effective dose and monitor for hypotension.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker used for hypertension. It has high vascular selectivity and minimal negative inotropic effects. Avoid use in patients with advanced aortic stenosis. Dose adjustment may be needed in elderly or hepatic impairment. Can cause gingival hyperplasia; maintain good oral hygiene.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed, usually twice daily.,Do not stop suddenly without consulting your doctor.,May cause dizziness or lightheadedness; avoid driving if affected.,Report any swelling of gums, ankles, or feet.,Avoid grapefruit juice as it can increase drug levels.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC vs ADALAT, answered by our medical review team.
DYNACIRC is a Calcium Channel Blocker that works by Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC is: 2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC is classified as Category C. First trimester: No adequate studies; animal reproduction studies not available. Second trimester: Possible fetal bradycardia, hypotension, hypoxia if used after 20 weeks due to ca. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.